Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m (Jwarner moved page AG-221 to Enasidenib (Idhifa): FDA approval) |
m |
||
| (23 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | IDH2 | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=752247 NCI Drug Dictionary]: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf Enasidenib (Idhifa) package insert]</ref> |
| − | [[Category: | + | ==Diseases for which it is used== |
| − | [[Category: | + | *[[Acute myeloid leukemia, IDH-mutated]] |
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2017-08-01: Granted [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm FDA regular approval] for the treatment of adult patients with relapsed or refractory [[Acute myeloid leukemia|acute myeloid leukemia]] with an [[Biomarkers#IDH2|isocitrate dehydrogenase-2 (IDH2)]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. ''(Based on AG-221-C-001 relapsed)'' | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2019-02-06: Initial notice of compliance with conditions for the treatment of adult patients with relapsed or refractory [[Acute myeloid leukemia|Acute Myeloid Leukemia (AML)]] with an isocitrate dehydrogenase-2 IDH2 mutation. | ||
| + | ==Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf Enasidenib (Idhifa) Package Insert] | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' AG-221, CC-90007 | ||
| + | *'''Generic name:''' enasidenib mesylate | ||
| + | *'''Brand name:''' Idhifa | ||
| + | ==References== | ||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
| + | |||
| + | [[Category:Acute myeloid leukemia medications]] | ||
| − | |||
[[Category:IDH2 inhibitors]] | [[Category:IDH2 inhibitors]] | ||
| + | |||
| + | [[Category:FDA approved in 2017]] | ||
| + | [[Category:Health Canada approved in 2019]] | ||
Latest revision as of 17:48, 1 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]
Diseases for which it is used
History of changes in FDA indication
- 2017-08-01: Granted FDA regular approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Based on AG-221-C-001 relapsed)
History of changes in Health Canada indication
- 2019-02-06: Initial notice of compliance with conditions for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an isocitrate dehydrogenase-2 IDH2 mutation.
Patient Drug Information
Also known as
- Code names: AG-221, CC-90007
- Generic name: enasidenib mesylate
- Brand name: Idhifa